Related Experiment Video
Updated: Jan 19, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Elimination of HER3-expressing breast cancer cells using aptamer-siRNA chimeras
Inga Nachreiner1, Ahmad Fawzi Hussain2, Ulrich Wullner3
1Department of Research and Development, Grünenthal GmbH, D-52078 Aachen, Germany.
Abstract:
Breast cancer is the most common cancer in women worldwide. Despite recent developments in breast cancer detection and treatment, 1.38 million women each year are still affected. Breast cancer heterogeneity at the population and single-cell level, complexity and developing different metastases are setting several challenges to develop efficient breast cancer therapies. RNA interference (RNAi) represents an opportunity to silence gene expression and inhibit specific pathways in cancer cells. In order to reap the full advantages of RNAi-based therapy, different pathways that sustain cancer cells growth have been targeted using specific siRNAs. The present study investigated the ability of a set of cytotoxic siRNAs to inhibit growth of breast cancer cells. These siRNAs are targeting eukaryotic elongation factor 2 (EEF2), polo-like kinase 1 (PLK1), G protein-coupled receptor kinase 4 (GRK4) and sphingosine kinase interacting protein (SKIP5). To facilitate their targeted delivery, the human epidermal growth factor receptor-3 (HER3)-specific aptamer A30 was used. The in vitro results described in this work indicate that combining the highly specific HER3 aptamer with cytotoxic siRNAs targeting (EEF2, PLK1, GRK4 and SKIP5) can inhibit its activity and ultimately suppress proliferation of HER3 positive breast cancer cells.
Insights
This study shows that combining a HER3-specific aptamer with cytotoxic small interfering RNAs (siRNAs) targeting EEF2, PLK1, GRK4, and SKIP5 can inhibit breast cancer cell growth. This approach effectively suppresses proliferation in HER3-positive breast cancer cells.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Breast cancer remains a leading cause of mortality in women globally, presenting significant therapeutic challenges due to its heterogeneity and metastatic potential.
- RNA interference (RNAi) offers a promising strategy for gene silencing to target cancer cell growth pathways.
- Developing targeted therapies is crucial to overcome resistance and improve outcomes in breast cancer treatment.
Purpose of the Study:
- To investigate the efficacy of cytotoxic small interfering RNAs (siRNAs) in inhibiting breast cancer cell proliferation.
- To evaluate the potential of a HER3-specific aptamer (A30) for targeted delivery of siRNAs.
- To determine if combining aptamer-mediated delivery with specific siRNAs can suppress the growth of HER3-positive breast cancer cells.
Main Methods:
- Synthesized and utilized cytotoxic siRNAs targeting eukaryotic elongation factor 2 (EEF2), polo-like kinase 1 (PLK1), G protein-coupled receptor kinase 4 (GRK4), and sphingosine kinase interacting protein (SKIP5).
- Employed the HER3-specific aptamer A30 for targeted delivery of the cytotoxic siRNAs.
- Conducted in vitro experiments to assess the impact of the combined therapy on HER3-positive breast cancer cell proliferation.
Main Results:
- The HER3-specific aptamer A30 successfully facilitated targeted delivery of the cytotoxic siRNAs.
- The combination therapy demonstrated significant inhibition of breast cancer cell proliferation.
- Targeting EEF2, PLK1, GRK4, and SKIP5 via siRNA, delivered by the A30 aptamer, effectively suppressed cancer cell activity.
Conclusions:
- Combining a HER3-specific aptamer with cytotoxic siRNAs targeting key growth pathways is a viable strategy for inhibiting HER3-positive breast cancer.
- This targeted RNA interference approach shows potential for developing novel breast cancer therapies.
- Further research into aptamer-siRNA conjugates could lead to more effective and specific breast cancer treatments.
